Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

The Food and Drug Administration has approved a highly effective new HIV prevention medication, known as Yeztugo. In clinical ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...

The US Food and Drug Administration (FDA) has approved use of the vaccine Yeztugo, manufactured by Gilead Sciences, is an anti-HIV drug.

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

The US FDA has approved lenacapavir, a biannual injection by Gilead, to prevent HIV, potentially revolutionizing the fight against the epidemic.

FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...